{{ variable.name }} : {{ variable.values[selectedVariantsIndex[variable_index]].name }}
Quantity:
AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal region (amino acids 176–191) of human growth hormone (hGH), with an added tyrosine residue for stability.
What It Is & How It Works
• Mechanism: It is designed to mimic the fat-mobilizing (lipolytic) domain of human growth hormone. It stimulates fat breakdown (lipolysis) and inhibits fat storage (lipogenesis) in adipose tissue, theoretically through beta-3 adrenergic receptor pathways. Journal of Endocrinology and Metabolism +2
• Difference from Full HGH: Unlike full-length growth hormone, AOD-9604 does not bind to growth-hormone receptors, meaning it does not raise IGF-1 levels, cause insulin resistance, impair glucose tolerance, or promote bone/organ growth.
Clinical Status & Regulatory Reality
• Clinical Trial History: While early animal studies and small trials showed promise for fat reduction, larger clinical trials (such as a Phase IIb study of over 500 participants) failed to show statistically significant weight loss compared to a placebo at the 12-week mark, leading developers to halt formal pharmaceutical development.
Proposed Administration & Potential Limits
• Administration: In informal or research protocols, it is commonly discussed as a subcutaneous injection (often split into daily doses of 250–300 mcg), though clinical evidence for optimal dosing in humans is sparse. ubiehealth.com +1
• Why Results Vary: Practical reviews on compounds like Ubie Health note that real-world outcomes are highly inconsistent and heavily dependent on baseline diet, exercise, product purity, and proper storage